Ohsu Knight Cancer Institute
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 63
- Registration Number
- NCT04965311
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 98
- Registration Number
- NCT04946279
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
๐บ๐ธPortland VA Medical Center, Portland, Oregon, United States
Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 15510
- Registration Number
- NCT04890054
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04872790
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT04850599
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT04814524
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Virtual Reality Experiences for Anxiety and Pain Control
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT04759183
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT04659616
- Locations
- ๐บ๐ธ
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
๐บ๐ธOHSU Knight Cancer Institute, Portland, Oregon, United States
War on Melanomaโข Public Health & Education Campaign
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 75000
- Registration Number
- NCT04611568
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT04539808
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath